GlassScriptPhysician profile
Yuen C Cheng
NPI 1841545647
$15,558.17
in general payments reported to CMS, 2019-2025
28 companies · $1,105 in 2025
The $1,105 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,202 · 2020: $1,664 · 2021: $3,218 · 2022: $2,663 · 2023: $2,573 · 2024: $1,134 · 2025: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,965 · Travel and Lodging: $847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,964.55 |
| Travel and Lodging | $847.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $8,181.03 | 2019-2025 | Proclaim, Eterna, Octrode |
| Spinal Simplicity, LLC | $2,134.84 | 2021-2023 | Ha Minuteman G3-R |
| Medtronic, INC. | $2,060.69 | 2022-2025 | Synchromedii, Vanta Adaptivestim, Intellis Adaptivestim |
| Boston Scientific Corporation | $700.81 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Vertiflex, INC. | $431.32 | 2019 | |
| Si-Bone, INC. | $300.74 | 2019-2024 | |
| Relievant Medsystems, INC. | $196.12 | 2022-2023 | Intracept |
| Curonix LLC | $191.96 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Nalu Medical, INC. | $186.64 | 2023 | Nalu Neurostimulation System |
| Foundation Fusion Solutions, LLC | $180.04 | 2021-2023 | |
| Painteq LLC | $175.24 | 2021-2022 | |
| Stryker Corporation | $148.47 | 2019 | |
| Glaxosmithkline, LLC. | $121.85 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $110.91 | 2022 | |
| Bioventus LLC | $60.14 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $44.25 | 2023 | Senza |
| Redhill Biopharma INC. | $44.09 | 2021 | |
| Pfizer INC. | $38.25 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $33.24 | 2021 | |
| Grt US Holding, INC. | $32.92 | 2022 | |
| Medtronic USA, INC. | $32.18 | 2019 | |
| Abbvie INC. | $32.04 | 2021 | |
| Collegium Pharmaceutical, INC. | $25.66 | 2021-2022 | |
| Averitas Pharma INC. | $25.44 | 2023 | Qutenza |
| Novartis Pharmaceuticals Corporation | $20.98 | 2021 | |
| Valinor Pharma, LLC | $19.49 | 2023 | Movantik |
| Ibsa Pharma INC. | $15.32 | 2021 | |
| Forte Bio-Pharma LLC | $13.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuen Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.